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Resumo 
Lesões a nervos periféricos se constituem num problema clínico global que, normalmente, 
resulta em recuperação ausente ou incompleta, reduzindo a qualidade de vida de inúmeros 
pacientes. O reparo de tais lesões depende de abordagem cirurgia, sendo rotineiramente 
empregada a neurorrafia término-terminal, considerada padrão ouro, com os melhores 
resultados clínicos. Quando o reparo direto não é possível, devido à retração dos cotos, utiliza-
se o enxerto autólogo, a partir de nervos doadores. Ao passo que as técnicas cirúrgicas têm 
propiciado os melhores resultados práticos, o grau de recuperação se mostra aquém do 
esperado, além de ser altamente variável. Portanto, o desenvolvimento de novas estratégias que 
possam otimizar o processo regenerativo, após reparo nervoso periférico, é necessário. Neste 
sentido, a terapia celular surge como promissora opção. Assim, o transplante de células tronco 
embrionárias humanas (hESCs) mostra-se uma abordagem viável, tendo em vista a 
pluripotência, que resulta na possibilidade de substituição de elementos celulares do nervo, 
além da capacidade de se dividirem indefinidamente. Contudo, as hESCs necessitam de 
constante aporte exógeno de FGF2 para manter sua capacidade de auto-renovação e 
pluripotência, bem como para conduzir a diferenciação em diferentes tipos celulares. O FGF-2 
exógeno pode estimular a expressão de genes fundamentais das células tronco, assim como 
eliminar morte celular por suprimir genes pró-apoptóticos. O objetivo principal do presente 
estudo é encontrar condições ideais para a recuperação funcional após neurorrafia término-
terminal. Para isso, postulamos que hESCs sozinhas ou combinadas com arcabouço de fibrina 
possam ser empregadas para sustentar a regeneração axonal em camundongos submetidos à 
neurorrafia término-terminal. Dessa forma, o nervo ciático de camundongos C57BL/6J foi 
transeccionado (5mm) e, após rotação de 180º, tal segmento foi suturado simulando o enxerto 
término-terminal, ligando os cotos proximal e distal. Quando previsto, foi aplicado o selante de 
fibrina e/ou hESCs alteradas geneticamente para superexpressar FGF2 no local da lesão. O 
estudo foi desenhado de forma a serem formados seis grupos experimentais: neurorrafia (N), 
neurorrafia+selante de fibrina (N+F), neurorrafia+selante de fibrina+doxicilclina (N+F+D), 
neurorrafia+selante de fibrina+hESCs selvagens (N+F+W), neurorrafia+selante de 
fibrina+hESCs não induzidas (N+F+T) e neurorrafia+selante de fibrina+hESC induzidas a 
produzir FGF2 (N+F+D+T). Foi avaliada a recuperação funcional da marcha utilizando-se o 
sistema CatWalk, bem como o limiar nociceptivo pelo método de von-Frey. O processo 
regenerativo foi estudado por imunoistoquímica, com marcadores para fibras motoras e 
sensitivas, bem como para reatividade das células de Schwann. Os resultados indicaram 
melhora na sensibilidade quando as hESCs foram utilizadas, na forma induzida para expressar 
FGF2. A regeneração das fibras sensitivas levou à melhora do reflexo de retirada, em resposta 
à estimulação da planta da pata ipsilateral à lesão, fato corroborado pela análise 
imunoistoquímica. O sistema CatWalk, contudo, não mostrou diferenças significativas na 
recuperação da marcha, comparando-se os grupos estudados. Conclui-se, portanto, que o 
emprego de hESCs, modificadas geneticamente para superexpressar FGF2 de forma induzida, 
pode ser útil como suporte adicional ao processo regenerativo, melhorando a regeneração 
axonal, especialmente do componente sensitivo. 
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Abstract 
Peripheral nerve injury is a worldwide clinical problem that often results to incomplete or no 
functional recovery, thus impairing the quality of life of many patients. To repair such injuries, 
a type of surgical operation is commonly involved. The preferred surgical method for this aim 
is the direct nerve repair (end-to-end neurorrhaphy) as it provides the best functional outcomes. 
Where the end-to-end suturing is not possible due to large nerve gap, autologous nerve grafting 
is used as the gold standard alternative. Whereas such surgical techniques have proved to lead 
to better nerve regeneration, the degree of recovery is shown to be highly variable. It is thus 
very important to seek complementary techniques to improve the degree of recovery. One of 
the promising technique for this aim could be cell therapy. Transplantation therapy by human 
embryonic stem cells (hESCs) is very appealing because they are true pluripotent that can 
differentiate into specialized cell type and have the ability to self-renew indefinitely. However, 
the hESCs require exogenous FGF-2 to sustain self-renewal and pluripotency, and develop the 
capacity to differentiate into a large number of somatic cell types. The exogenous FGF-2 can 
also stimulate the expression of stem cell genes while eliminating cell death and apoptosis 
genes. The main objective of this research is to find conditions under which functional recovery 
is improved after sciatic nerve neurorrhaphy. We assumed that hESC, either alone or in 
combination with fibrin sealant scaffold, could be used to support regeneration in a mouse 
model of sciatic nerve injury and repair via autografting with end-to-end neurorrhaphy. To 
fulfill this objective, we transected 5 millimeters of the sciatic nerve of C57BL/6J mice and 
inverted by 180° to simulate an injury, and then sutured the stumps. Next, we applied fibrin 
sealant and/or human embryonic stem cells altered genetically to overexpress FGF2 at the site 
of injury. The study was designed to include six experimental groups comprising neurorrhaphy 
(N), neurorrhaphy + fibrin sealant (N+F), neurorrhaphy + fibrin sealant + doxycycline 
(N+F+D), neurorrhaphy + fibrin sealant + wild type hESC (N+F+W), neurorrhaphy + fibrin 
sealant + hESC off (N+F+T), and neurorrhaphy + fibrin sealant + hESC on via doxycycline 
(N+F+D+T). We evaluated the recovery rate using Catwalk and von Frey tests and 
immunohistochemistry analysis under a fluorescence microscope. The experiments indicated 
that sensory function improved when transgenic hESCs were used. The regeneration of sensory 
fibers indeed led to increased reflexes, upon stimulation of the paw ipsilateral to the lesion, as 
seen by von-Frey evaluation and supported by immunohistochemistry. The Catwalk system, 
however, was not successful in showing the functional recovery, likely due to its incapability 
to record partial paw usage with this particular animal model. Our work indicated that the 
simultaneous use of sensory test (von Frey) and Catwalk could provide a more detailed picture 
of sciatic nerve recovery. Overall, our research demonstrated that transgenic embryonic stem 
cells, engineered to overexpress FGF-2, could be employed to support regeneration aiming at 
the recovery of both motor and sensory function. 
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1. Introduction 
1.1. The Nervous System 
The nervous system is didactically divided into two main parts namely Central Nervous 
System (CNS) and Peripheral Nervous System (PNS). The functions of the nervous system 
involve the processing of sensory information, motor control, mediation of autonomic 
responses, elaboration of emotional responses, learning, and memory(Kandel, Schwartz et al. 
2000).  
Whereas CNS includes all parts of the brain and spinal cord, PNS is composed of 
peripheral nerves and ganglia. The latter is a small group of nerve cells outside the CNS. 
Neurons are specialized cells in the conduction of the nerve impulse and constitute the 
fundamental unit of the nervous system. A typical neuron is composed of a body (soma), 
dendrites and an axon (MACHADO 2006). Peripheral nerves contain groups of axons (nerve 
fibers) that bundle together (Mescher 2009). Within a nerve, each axon is surrounded by a layer 
of connective tissue called the endoneurium. The axons are bundled together into groups called 
fascicles. Each fascicle is wrapped in a layer of connective tissue called the 
perineurium. Ultimately, the entire nerve is wrapped in a layer of connective tissue called 
epineurium (Flores, Lavernia et al. 2000)  (Fig. 1).  
 12 
 
Fig. 1. An overview of the PNS. The axons surrounded by myelinating Schwann cells are 
enclosed by endoneurium. The perineurium binds individual axons together to form fascicles 
and epineurium groups fascicles to form the nerve cable (Marieb, Mitchell et al. 2013).  
The cell body of the neuron is considered to be the metabolic center responsible for the 
synthesis of most of the neuronal proteins and the degradation and renewal of the cellular 
constituents. Dendrites, on the other hand, are responsible for receiving and generating stimuli. 
The axon originates in the body of the neuron in a region named the cone of 
implantation(Kandel, Schwartz et al. 2000). The length of axons are variable and in the human, 
for example, varies from a few millimeters to more than one meter. The same applies to the 
axons of the neurons that form the sciatic nerve. The axon is specialized in the conduction of 
the electrical impulse and is responsible for the transport of substances such as neurotrophins 
and growth factors. This transport is provided from the cellular body to the axonal terminals 
and vice versa, which are respectively called the antegrade and retrograde axoplasmic 
flow(MACHADO 2006). The cell, as a whole, receives terminals or synaptic buttons from other 
neurons and forms synapses. 
Axons in the PNS are surrounded by Schwann cell processes allowing close contact and 
metabolic relationship. In myelinated axons, Schwann cells produce the myelin sheath around 
each axon to protect and direct the nerve impulses. Every Schwann cell forms its internodal 
myelin sheath, which is separated from an adjacent internode by a node of Ranvier. As a result, 
Schwann cells are aligned discontinuously along the axon and are separated by nodes of Ranvier 
at both the proximal and distal ends of the internode(Ide 1996).   
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The PNS can be divided into two parts namely somatic and visceral. The visceral 
(autonomic) PNS consists of neurons that innervate the internal organs, blood vessels, and 
glands. Its sensory part carries information about the visceral function to the CNS, whereas the 
motor part commands the contraction and relaxation of smooth muscles(Bear, Connors et al. 
2008). The somatic PNS, on the other hand, is formed by axons that innervate the skin, joints, 
and skeletal striated muscles, acting under voluntary control. Somatic motor axons command 
muscle contraction under the control of motoneurons, whose cellular bodies are located in 
nuclei in the ventral portion of the spinal cord(Bear, Connors et al. 2008). Somatic sensory 
fibers, in turn, innervate and collect information from the skin, muscles and joints, and reach 
the spinal cord via dorsal roots. The cellular bodies of these neurons are located outside the 
CNS in the dorsal root ganglia(Bear, Connors et al. 2008). 
After leaving the spinal cord or the sensory ganglia, the nerve fibers combine to form 
peripheral spinal nerves, such as the sciatic nerve(MACHADO 2006). The sciatic nerve, which 
is formed by the ventral roots of the spinal nerves namely L4, L5, L6 in the mouse, is the largest 
nerve in the body and is part of the lumbosacral plexus. The sciatic nerve itself is formed by 
three branches including: (i) tibial nerve, (ii) common fibular nerve, and (iii) sural 
nerve(MACHADO 2006). 
1.2. Peripheral Nerve Injury 
Since neurons have long axons and relatively small cell bodies, most injuries in both the 
CNS and the PNS involve axonal damage. Due to superficial pathways of the peripheral nerves 
in some parts of the body, they are subject to various types of injuries including crushing and 
transection (Sunderland 1990, Schmidt and Leach 2003). The most severe, however, is the 
complete transection of a nerve called axotomy. Following an axotomy, several molecular and 
cellular changes are observed at the level of the cell body, at the site of injury, and in the target 
organs (Faroni, Mobasseri et al. 2015). 
Initially, the axotomy divides the axon into a proximal segment, which remains attached 
to the cell body, and a distal segment that, due to the lesion, loses its connection with the soma. 
The cell body reaction leads to a profound response in both gene and protein expression. The 
balance of these determines whether the neuron survives and attempts regeneration or results 
in apoptotic death. Because the ability of protein synthesis is mostely restricted to the cell body, 
axotomy gives rise to degeneration of the distal segment (Faroni, Mobasseri et al. 2015). In the 
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proximal portion of the lesion, the cell body undergo a series of changes in response to injury, 
the so-called chromatolysis, including: (i) swollen cell body, (ii) displacement of the nucleus to 
the periphery and fragmentation of the rough endoplasmic reticulum. Metabolic changes 
consisting of an overall increase in protein and RNA synthesis and changes in the gene pattern 
expressed by neurons can also accompany the noted reaction (Kandel, Schwartz et al. 2000). 
Typically, the injured neurons prioritize the synthesis of proteins related to axon repair and 
growth. These changes are reversible if nerve regeneration is successful (Zochodne 2000). 
The distal stump (distally to the lesion site) of the injured nerve undergoes a series of 
molecular and cellular changes known as Wallerian degeneration, which has a crucial role in 
the degeneration of the distal fragments of the injured axons. Schwann cells release myelin, 
proliferate and produce cytokines and trophic factors, and participate in phagocytosis of myelin 
debris and thus degenerating axons. The soluble factors produced by Schwann cells, combined 
with axon debris activate resident macrophages and attract blood borne macrophages. When 
the fragmented debris are removed by the combined action of Schwann cells and macrophages, 
the former align to form columns called bands of Büngner. Such arrangement creates a 
permissive environment rich in trophic factors, enabling guided axonal regeneration 
(Sunderland 1990, Ide 1996, Bruck 1997, Faroni, Mobasseri et al. 2015). 
In the target organ level, there are several obstacles for the regeneration of axon prior to 
successful reinnervation. Typically, any misdirection towards the wrong target reduces 
functional outcome even if there are a good number of regenerated axons. A lack of neuronal 
contact in the distal stump leads to chronically denervated Schwan cells that down-regulate 
growth factors and thus become unable to support axonal progression. 
Similarly, the denervated target organ becomes depleted of trophic factors, resulting in 
muscle fibres atrophy, leading to satellite cells apoptosis. These responses bear a significant 
impact on functional recovery following proximal nerve injuries (Faroni, Mobasseri et al. 
2015). 
1.3. Nerve Regeneration (Peripheral nerve repair) 
The PNS has far greater potential for regeneration than the CNS, mainly because the 
former is associated with Schwann cells (Ren, Wang et al. 2012). Following an injury in the 
PNS, Schwann cells transform into repair cells in the distal nerve stump. These cells, along with 
macrophages, clean up inhibitory debris and enable the new axon sprouts to grow into the 
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degenerating nerve by the guidance of bands of Büngner. The result of these events is a healthy 
environment for regeneration in the PNS(Scheib and Hoke 2013). 
In the case of severe injuries, nerve regeneration commences only when Wallerian 
degeneration has evolved its course. The degenerative process involves a mechanism to convert 
normal nerves from a suppressed state into a state that promotes axonal growth (Salonen, 
Peltonen et al. 1987, Danielsen, Kerns et al. 1995, Burnett and Zager 2004). Thus, the 
regeneration process, as stated by Burnett et al. may be divided into the following anatomical 
zones: “ (i) the neuronal cell body; (ii) the segment between the cell body and the injury site; 
(iii) the injury site itself; (iv) the distal segment between the injury site and the end organ; and 
(iv) the end organ itself “ (Burnett and Zager 2004). 
The regeneration of an injured nerve may take several months. The first signs of this 
process are the reversal of chromatolysis in the cell body and the centralization of the nucleus. 
This signifies a fundamental shift in cell function from synaptic transmission to cellular repair. 
The cell body regulates the metabolism to enable it to produce the vast amount of proteins and 
lipids needed for axonal regrowth during the regeneration phase. Axoplasm, which is 
responsible for the regeneration of the axon tip, arises from the proximal axon segment and cell 
body. The rate of protein and lipid synthesis in the cell body affects the progress rate and the 
final size of the regenerating axon (Burnett and Zager 2004). 
The rate of axonal regrowth is regulated by (i) modification in the cell body, (ii) the 
activity of the growth cone at the end of axon sprout, and (iii) the strength of the injured tissue 
located between the cell body and end organ (Burnett and Zager 2004). 
Axons that successfully enter the endoneurial tubes in the segment distal to the injury 
site are more likely to reach the end organ. When the endoneurial tubes have been disrupted, 
axon sprouts must first find their way into the tubes before advancing. This is achieved by 
specialized growth cone at the tip of each axon, sprouting filopodia that adhere to the basal 
lamina of the Schwann cell and use it as a guide. Accordingly, successful axonal regeneration 
is entirely dependent on axonal sprouts making appropriate contact with Schwann cell basal 
lamina in the distal nerve segment (Muir 2010). Regenerating axonal sprouts usually follow the 
original Schwann cells to the denervated motor endplates to reform neuromuscular junctions. 
There are chances for co-lateral sprouting to occur that result in groups of reinnervated muscle 
fibers (Burnett and Zager 2004). During the regeneration, the axon’s diameter increases 
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progressively until reaching close to normal dimensions, but this growth is dependent on the 
establishment of functional connections between the axon tip and the appropriate end organ 
(Burnett and Zager 2004). 
The transition of the nerve environment from an inhibited state to a regeneration 
promoting one is likely an important event governing the onset and progression of axonal 
regrowth. The degenerative process appears to involve mechanisms that convert normal nerve 
from a suppressed state to one that promotes axonal growth (Salonen, Peltonen et al. 1987, 
Danielsen, Kerns et al. 1995). 
1.4. Direct Nerve Repair (Neurorrhaphy) 
Following an injury that interrupts the nerve continuity, the primary repair is a standard 
surgical procedure called “direct nerve repair” or “neurorrhaphy” (Hayat 2012). This surgical 
technique can be achieved in two ways: end-to-end (ETE) repair, in which the coaptation is 
performed between proximal and distal nerve stumps, and end-to-side (ETS) repair, in which 
the coaptation is performed between the distal nerve stump and another healthy donor nerve 
(Lundborg 1993, Hayat 2012). If direct end-to-end repair is not possible, due to retraction of 
the stumps, autografting using sensory donor nerves is the gold standard approach. 
Some pre-clinical studies have attempted to compare the effectiveness of ETE and ETS 
techniques in the context of nerve preservation and nerve regeneration. The results have 
demonstrated the superiority of the ETE neurorrhaphy over the latter in terms of recovery time 
and the strength of the re-established motor force (Liao, Chen et al. 2009). 
ETE neurorrhaphy repair may be performed by epineural, perineurial (Fascicular or 
Funicular), and group fascicular techniques (Mafi, Hindocha et al. 2012). Conventionally, 
however, the epineural repair, in which the stitches passed through the epineurium, has been 
widely in use. There are several advantages to this technique including short execution time, 
minimal magnification, technical easiness, not invading the intraneural contents, applicability 
to both primary and secondary neural repairs, and the placement of sutures only in the outer 
investing sheath (Daniel and Terzis 1977). 
Whereas suturing the ends of the two nerves together can repair small defects or gaps in 
the nerve (Schmidt and Leach 2003), there are cases that large lesion gaps in the peripheral 
nervous system due to a defect, scar, or neuroma in continuity hinders direct repairing without 
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considerable tension. Such damages cannot be directly repaired without excessive tension and 
impeding or limiting regeneration. When the gap that must regenerate across is above the 
critical gap, a graft is needed to bridge the damaged ends, reconnecting the proximal and distal 
stumps, and preventing the formation of a neuroma (Muir 2010). In such situations, ‘autogenous 
nerve grafting’ is considered as the standard clinical treatment, particularly when there is tissue 
loss and direct repair is not possible (Hayat 2012, Cartarozzi, Spejo et al. 2015). In this grafting 
technique, a comparable nerve is first removed from another part of the patient's body and is 
used to bridge the gap and connect the two ends of the severed nerve (Lundborg 2004, Glynn 
2007). Without such grafts, these injuries will possibly never heal and can be permanently 
debilitating (Muir 2010). For longer nerve gaps, however, this approach is not desired, because 
tensions introduced into the nerve cable could inhibit nerve regeneration (Schmidt and Leach 
2003). 
There are several reasons for universal acceptance of autologous grafting in major 
peripheral nerve repair. The first one is that by taking the donor nerve from within the patient's 
body, there is no immune-rejection. This procedure offers a cell-rich material through which 
axons can regenerate and thus has a relatively high success rate in restoring the majority of the 
functionality to the damaged targets. It offers neuro-supportive architecture (that promotes 
subsequent regeneration), guidance cues, neurotrophic factors, and a source for Schwann cells 
(Lundborg 2004, Glynn 2007, Noaman 2012). Nerve regeneration with autografts usually 
utilizes much of the graft's sheath arrangement and topology (Muir 2010). 
By comparison, commercially available substances such as biodegradable polymer and 
collagen-based hollow tubes have failed to match the regenerative levels of autologous nerve 
grafting, mainly because they are limited to small defects and show poor functional recovery 
(Faroni, Mobasseri et al. 2015). Direct nerve repair can be performed by means of fibrin glue, 
or nylon suturing; however, the latter is the most common method used for this aim (Hayat 
2012).  
To simulate the autogenous nerve grafting in the lab, 5 millimeters of the sciatic nerve 
of a mouse is transected, inverted by 180°, and then is sutured or glued (e.g. with fibrin sealant) 
(Evans, Bain et al. 1991). The plan to invert the nerve of the same animal intend to minimize 
the number of animals and their pain and discomfort. However, nerve repairs performed with 
fibrin sealant is demonstrated to produce less inflammation, less fibrosis, better axonal 
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regeneration, and better fiber alignment in comparison with the nerve repair performed using 
merely microsuturing (Pabari, Lloyd-Hughes et al. 2014). 
1.5. Human Embryonic Stem Cells (hESC) 
Although some surgical techniques have proved to lead to better nerve fiber 
regeneration, the degree of recovery can be highly variable (Samii, Carvalho et al. 1997, 
Lundborg 2002). It is thus crucial to seek for complementary techniques to improve the level 
of recovery. 
In recent years, stem cells have been widely investigated to be used to complement 
surgery and facilitate the repair of injured peripheral nerves. The sources of these stem cells are 
widespread and among them are the embryonic stem cells (ESC) routinely derived from the 
inner cell mass of blastocysts (Evans and Kaufman 1981, Thomson, Itskovitz-Eldor et al. 1998, 
Rahaman and Mao 2005, Ren, Wang et al. 2012). Due to the ability of ESC to self-renew 
indefinitely and their pluripotency character, they have been considered as an ideal source of 
cells for biomedical engineering (Weissman 2000).  
 
Fig. 2. The steps for obtaining human embryonic stem cells (after Terese Winslow, 2006). 
Although not completely clarified, the delivery of cellular components to the injured 
nerve is based on the potential structural and neurotrophic additive effects exerted by paracrine, 
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differentiation and cell fusion mechanisms. Many kinds of cells including Schwann cells, 
embryonic, fetal, and adult stem cells have been considered as candidates for transplantation 
therapy in the peripheral nervous system (Hayat 2012). 
The effectiveness of ESCs for the treatment of peripheral nerve injury and functional 
recovery may lie in their ability to differentiate into Schwann cells, secrete neurotrophic factors, 
promote axon regeneration, and assist in myelin formation (remyelination of axons). 
Myelination, which determines both regeneration quality and functional recovery, requires the 
longitudinal wrapping of Schwann cells (Ren, Wang et al. 2012). Also, these cells could be 
induced to express a neural phenotype before transplantation (Hayat 2012).  
Some researchers have shown that ESC transplantation can be a successful treatment. 
For example, Cui et al. (Cui, Jiang et al. 2008) transplanted pre-differentiated ESC after sciatic 
nerve axotomy in rats, and after three months observed that cells integrated with the host tissue 
and demonstrated as expressing Schwann cell markers, suggesting that, at least part of the 
remyelination process was performed by the transplanted cells. Regenerated axons were also 
recorded, showing the uniform connection between the proximal and distal stumps and giving 
rise to functional activity across the injury gap (Cui, Jiang et al. 2008). 
However, there are many issues to be solved before the ESC can be used in nerve 
therapy. Before being transplanted, these cells must be expanded invitro and differentiated, as 
the undifferentiated cells can multiply in an uncontrolled manner upon injection, leading to 
teratomas (Mendez-Otero, de Freitas et al. 2007). Human ESC (hESC) are traditionally 
maintained in colonies on the feeder cell layers, formed for example by mitotically inactivated 
mouse embryonic fibroblasts (MEF). It is nowadays accepted that the most technological way 
to propagate hESC is to grow them in monolayers using Matrigel, laminin, or other extracellular 
matrix components as a substrate (Kunova, Matulka et al. 2013). Various cytokines and growth 
factors are used to support self-renewal of hESC in different culture systems, while the presence 
of fibroblast growth factor 2 (FGF-2) is absolutely necessary (Dvorak, Dvorakova et al. 2006). 
Advanced cellular bioengineering methods can provide ways to change useful 
properties of the stem cells according to the objectives of the usage. This can offer opportunities 
to seek for the treatment of tissues with little or no regenerative capacity including the 
CNS(Kyrylenko 2012, Steward, Sridhar et al. 2013). Based on current knowledge, the engrafted 
cells can perform their supportive role by two possible mechanisms: (i) Replacing the missing 
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cellular elements, not only neurons but also supporting cells, particularly the 
Oligodendrocytes/Schwann cells that form myelin sheaths around axons; and (ii) Delivering 
trophic factors (Pêgo, Kubinova et al. 2012). The effects of cell therapy are mediated by the 
secretion of growth factors or cytokines that reduce neuronal apoptosis and inflammation and 
stimulate endogenous regenerative processes as well as re-myelination and neural plasticity, 
leading to the collateral sprouting of intact or damaged axons of the descending pathways 
(Bradbury and McMahon 2006, Pêgo, Kubinova et al. 2012). 
The application of growth factors can result in significant increase in nerve regeneration. 
However, it is difficult to deliver the active growth factors over the entire duration of 
regeneration in a controlled manner. Transplanted genetically modified cells, on the other hand, 
offer advantages as a means of delivering a continual supply of active growth factors. 
Furthermore, if the gene expression in the modified cells can be turned on (presence) and off 
(absence), which is achieved by using doxycycline as the regulator for inducible gene 
expression systems (Blesch, Lu et al. 2002), the expression then could be directed in a 
sophisticated manner. The ability to regulate gene expression in grafted cells by genetic 
engineering can enhance the in vivo efficacy of growth factor delivery by controlling axonal 
entry and exit from the lesion site. By this approach, a series of growth factor expression could 
lead axons to grow into a graft, switch patterns of expression, and then lead axons out of the 
graft. In addition, regulated expression of growth factors at distal sites of the lesion could 
enhance the exit of axons from the graft by attracting axons into the downstream regions 
(Blesch, Lu et al. 2002, Schmidt and Leach 2003).  
As noted, simple supplementation of hESC with doxycycline greatly improves the 
viability and self-renewal capability of the cells. In practice, doxycycline enhances the 
expandability of hESCs and boosts its effects for longer times. The effects of doxycycline are 
mediated by direct activation of the PI3K-AKT intracellular pathway, which has been reported 
to be the most crucial regulatory pathway for self-renewal of hESC (Chang, Rhee et al.). It is 
worth mentioning that doxycycline has neuroprotective function in PNS(Lazzarini, Martin et 
al. 2013, Santa-Cecilia, Socias et al. 2016, Gonzalez-Lizarraga, Socias et al. 2017). 
1.6. Fibroblast Growth Factor 2 
Fibroblast Growth Factor 2 (FGF-2, also known under the name Basic Fibroblast 
Growth Factor) is a representative growth factor that has shown potentials to effects the repair 
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and regeneration of tissues. Originally, it was identified as a protein with the capability to 
promote fibroblast proliferation. FGF exert multiple functions through binding into and 
activation of fibroblast growth factor receptors (FGFRs), and signaling through the stimulation 
of FGFRs is the RAS/MAP kinase pathway (Yun, Won et al. 2010).  
FGF-2 is a member of the FGF family, which comprises up to now 23 members (Ornitz 
and Itoh 2001) and encoded by a single copy gene that is alternatively translated to produce one 
low (18-kDa) and four high (22-, 22.5-, 24-, and 34-kDa) molecular mass isoforms (Arnaud, 
Touriol et al. 1999, Delrieu 2000).  
Recent studies on the function and expression of FGF-2 and its receptors have revealed 
a physiological role of these molecules in the PNS. FGF-2 and its receptors are constitutively 
expressed in the dorsal root ganglia and peripheral nerve (Grothe, Meisinger et al. 2001, Grothe 
and Nikkhah 2001). These molecules display an up regulation in the dorsal root ganglia and the 
proximal and distal nerve stumps following peripheral nerve injury. In the ganglia, the 
molecules show a chiefly neuronal expression, whereas at the lesion site of the nerve, Schwann 
cells and invading macrophages represent the main cellular sources of FGF-2 and the 1–3 
receptors (Grothe and Nikkhah 2001). Whereas Schwann cells are regarded as the main source 
of FGF-2(Grothe, Meisinger et al. 1996, Grothe and Nikkhah 2001), the autocrine function of 
FGF-2 is known to stimulate the Schwann cell proliferation 44; 45. 
After sciatic nerve injury, FGF-2 is shown to increase continually for at least four weeks 
in the proximal and distal nerve stump. The transcript levels of FGFR 1–3 are also upregulated 
proximal and distal to the lesion site (Grothe, Meisinger et al. 1996, Meisinger and Grothe 1997, 
Grothe and Nikkhah 2001). The isoforms of FGF-2 display a differential regulation in the nerve 
stumps before and after a lesion (Meisinger and Grothe 1997, Grothe, Heese et al. 2000, Grothe 
and Nikkhah 2001). 
Results from in vivo and in vitro studies using exogenously applied FGF-2 also indicate 
distinct functions for FGF-2 in spinal ganglia and at the lesion site (Grothe and Nikkhah 2001). 
It commonly promotes the neurite outgrowth and vascularization of the regenerating nerve 
fibers crossing the gap between proximal and distal stumps of the injured sciatic nerve 
(Danielsen, Pettmann et al. 1988, Aebischer, Salessiotis et al. 1989, Jungnickel, Haase et al. 
2006). Furthermore, it has been demonstrated that the use of FGF-2 to the transectioned sciatic 
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nerve can develop a neurotrophic capacity to rescue the sensory neurons from death (Otto, 
Unsicker et al. 1987). 
FGF-2 can also stimulate neurogenesis in animal models of neurodegenerative diseases 
(Peng, Xie et al. 2008, Woodbury and Ikezu 2014), stimulate synaptic plasticity (Terlau and 
Seifert 1990, Ishiyama, Saito et al. 1991), and be highly effective in promoting scarless wound 
healing (Abe, Yokoyama et al. 2012). Moreover, FGF-2 is a principal constituent of hESC 
growth medium and the most significant regulator of hESC self-renewal (Dvorak, Dvorakova 
et al. 2006). It is now widely accepted that hESCs require exogenous FGF-2 to sustain self-
renewal and pluripotency, and develop the capacity to differentiate into a large number of 
somatic cell types (Amit, Carpenter et al. 2000, Xu, Inokuma et al. 2001, Dvorak, Dvorakova 
et al. 2006). It activates the FGF receptors (FGFRs) and stimulates the mitogen activated protein 
kinase (MAPK) pathway in undifferentiated cells (Eiselleova, Matulka et al. 2009). Finally, the 
exogenous FGF-2 can stimulate the expression of stem cell genes while eliminating cell death 
and apoptosis genes. 
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2. Justification 
Peripheral nerve injury as a worldwide clinical problem could impair the quality of life 
of a patient and many of such injuries require surgical nerve reconstruction. This objective is 
mostly achieved by autogenous nerve grafting as gold standard treatments of the peripheral 
nervous system. Whereas suturing the ends of the two nerves together can repair small defects, 
there are cases in which large lesion gaps in the nerve hinders direct repairing without causing 
considerable tension. It is thus very important to seek complementary techniques to improve 
the degree of recovery. One of the promising technique for this aim is the use of cell therapy. 
Transplantation therapy by human embryonic stem cells is very appealing because they have 
the ability to self-renew indefinitely and differentiate into a diverse range of specialized cell 
types. The effective use of hESCs requires FGF-2 to sustain self-renewal and pluripotency and 
develop the capacity to differentiate into a large number of somatic cell types. In addition, nerve 
repairs performed with fibrin sealants was demonstrated to produce less inflammation, less 
fibrosis, better axonal regeneration, and better fiber alignment. Accordingly, a combination of 
hESCs which inducibly overexpress FGF-2 and fibrin sealants shall provide an ideal solution 
for nerve regeneration in mice model following autographing with end-to-end neurorrhaphy.    
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3. Research Objective 
 
3.1 General Purpose 
The main objective of this research is to find conditions under which functional recovery 
is improved after sciatic nerve neurorrhaphy. We assume that human embryonic stem cells 
(hESC), either alone or in combinations with fibrin sealant scaffold can be used to support 
neuronal survival and regeneration in a mice model of sciatic nerve injury and repair via 
autografting with end-to-end neurorrhaphy. 
3.2 Specific Objectives 
Specific objectives of this project are the following: (1) To investigate how human 
embryonic stem cells can be used to support functional recovery in a mice model of sciatic 
nerve isograft end-to-end neurorrhaphy; (2) To examine the effects of fibrin sealant on neuronal 
regeneration after sciatic nerve neurorrhaphy in mice; (3) To investigate how genetically 
engineered human embryonic stem cells, which inducibly overexpress human FGF-2, can be 
used to support neuronal regeneration; and (4) To examine the recovery and sensory function 
of animals subjected to sciatic nerve repair combined with hESC therapy and fibrin sealant 
through the walking track and Von Frey tests. 
 
  
 25 
4. Material and Methods 
 
4.1 Animals and Surgical Procedures  
To investigate the effect of different supplementary compounds (including fibrin 
sealant, doxycycline, and hESC) on the site of injury after neurorrhaphy, we designed six 
groups of 8 animals each and followed the procedures described in Table 1. 
Table 1 – Experimental groups and procedures followed during the research. 
 
Tag Group Abbreviations Procedure Number 
1 Neurorrhaphy alone N 
Immunohistochemistry 
Catwalk up to recovery 
(~8weeks post surgery) 
von Frey 
8 
2 
Neurorrhaphy + 
fibrin sealant 
N + F 
Immunohistochemistry 
Catwalk up to recovery 
(~8weeks post surgery) 
8 
3 
Neurorrhaphy + 
fibrin sealant + 
doxycycline 
N + F + D 
Immunohistochemistry 
Catwalk up to recovery 
(~8weeks post surgery) 
von Frey 
8 
4 
Neurorrhaphy + 
fibrin sealant + wild 
type hESC 
N + F + W 
Immunohistochemistry 
Catwalk up to recovery 
(~8weeks post surgery) 
von Frey 
8 
5 
Neurorrhaphy + 
fibrin sealant + 
hESC off 
N + F + T 
Immunohistochemistry 
Catwalk up to recovery 
(~8weeks post surgery) 
von Frey 
8 
6 
Neurorrhaphy + 
fibrin sealant + 
hESC on 
(doxycycline) 
N + F + D + T 
Immunohistochemistry 
Catwalk up to recovery 
(~8weeks post surgery) 
von Frey 
8 
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For sciatic nerve lesion and repair, four week-old C57BL/6 male mice were obtained 
from the Multidisciplinary Center for Biological Research (CEMIB), University of Campinas. 
We treated them in our lab for a period of 10 days by giving vermifuge medicine for three times 
with three days intervals. Both before, and after the surgery, the mice were kept with ad libitum 
access to food and water under controlled light (light/dark cycle of 12 h) and temperature 
conditions (i.e. 23°C) in racks specific for mice at our laboratory.  
The animals were anesthetized with intraperitoneal injections of Kensol (xylasine, 
Köning, Argentina; 10 mg/kg) and Vetaset (Cetamine, Fort Dodge, IA; 50 mg/kg, i.p); totaling 
0.12 ml/25 g of the body weight. The left hind of the animals underwent trichotomy. Then 
around 1.5 cm of the skin was incised with a scalpel. After exposing the sciatic nerve by 
retracting the musculature, a 5 mm long segment of the nerve was cut out from both ends, 
inverted by 180 degrees, and then inserted between the two nerve stumps. After inversion, the 
nerve was repaired according to the experimental groups and was sutured under the microscope 
with 9-0 nylon sutures (Fig. 3). During the surgical procedure, the first two components of the 
fibrin sealant were applied and the third component was added for polymerization. For those 
groups that embedded the fibrin sealant (Table 1), the cells were applied to the lesion site (6 µl) 
after adding the third component. The reimplantation stability was tested by gently pulling the 
nerve or by observing the clots of fibrin sealant at the site of suture under a microscope. 
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Fig. 3. Autografting procedure in which 5 millimeters of the sciatic nerve of a mouse is 
transected, inverted by 180°, and then is sutured or stitched together by nylon suture and fibrin 
sealant (~ 20x magnification). 
We kept the mice at ambient temperature (under the warmth of a lump) and waited for 
them to wake up. For groups # 3 and # 6, we gavaged 50 µl of 5 mg/ml of doxycycline instantly 
after mice got conscious. Doxycycline was also included in their feed for the duration of the 
experiments. 
All the mice underwent surgery and then maintained in a vivarium for more than eight 
weeks. During this period, we implemented a series of functionary and sensory evaluations 
using Catwalk and von Frey tests (sections 4-4 and 4-5). After the predetermined survival times, 
the animals were anaesthetized with an overdose of an aesthetic (a mixture of xylasine and 
ketamine). The vascular system was transcardially perfused with phosphate buffer 0.1M (pH 
7.4) and then perfused with 4% formaldehyde in phosphate buffer (20 ml of fixative per 
animal). Their sciatic nerve was dissected out and post fixed in the same fixative solution 
overnight at 4° C. They were then cryo-preserved for 24h in 10, 20, and 30% sucrose buffered 
solution, respectively. Before embedding in Tissue–Tek (MilesInc., USA) and freezing at 
−35°C to −40°C, we cut the nerves to yield proximal and distal parts. The longitudinal nerve 
sections with 12 μm thickness, prepared by a cryostat instrument, were obtained and transferred 
to gelatin-coated slides and stored at −20° C until use in immunohistochemistry studies (section 
4-6). 
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All the noted experiments were conducted following the rules of ethics in animal 
experimentation. We also endeavored to minimize the number of animals and their pain and 
discomfort. 
4.2 Vector Construction   
The Phusion High Fidelity DNA Polymerase (Finnzymes/Thermo Fisher Scientific, 
Vantaa, Finland) was used to amplify DNA fragments intended for cloning and/or transfections. 
For constructing the hFGF-2 bacterial overexpressing vector, a PCR fragment 475 bp in length 
was obtained using primers FGF-2-cds-2C, 5´-gaacatatggcagccgggagcatcac-3´ (with NdeI 
recognition site, underlined), and FGF-2-cds-2D, 5´-atccctcgagctagctcttagcagacattgg-3´ (with 
XhoI recognition site, underlined); and a template DNA from the ORFeome clone 
OCABo5050E0522D obtained from Source BioScience (Nottingham, United Kingdom). Its 
NdeI-XhoI subfragment 470 bp in length was then cloned into pET28b (Novagen/Merck 
Millipore, Darmstadt, Germany) using appropriate restriction endonucleases. The resulting 
vector pTe133 (GenBank accession number KX834270) was induced with IPTG in E.coli 
BL21(DE3) using EnPresso growth system from BioSilta Oy (Oulu, Finland) based on enzyme-
controlled glucose autodelivery. The soluble recombinant protein was purified using Ni affinity 
column. The (His)x6 tag was cleaved off by thrombin, and the resulting rFGF-2 was further 
purified using heparin affinity column. The biological activity of the purified rFGF-2 was 
verified using two methods: via cell proliferation assay in hESC; and then via the Erk 
phosphorylation assay in hESC.  
To obtain a stable hES cell line overexpressing FGF-2-GFP fusion in an inducible mode, 
a Tet-On system (Clontech/Takara Bio, Mountain View, CA, USA) was used. For constructing 
a vector for inducible overexpression of hFGF-2, a PCR fragments obtained with primers FGF-
2-cds-G, 5´-cagaattcatggcagccgggagcatc-3´ (with EcoRI recognition site, underlined) and FGF-
2-cds-H, 5´-tgggtaccaagctctta gcagacattgg-3 (with KpnI recognition site, underlined), 
containing ORF of hFGF-2, was cloned (477 kb) into respective sites of pEGFP-N1 (Clontech), 
giving rise to an intermediate vector pTe104, overexpressing hFGF-2-GFP fusion in a 
constitutive (non-inducible) mode. Then, the pTe104 was used as a template to amplify the 
fragment containing hFGF-2-GFP fusion ORF with the primer FGF-2-cds-G and a primer 
cdsGFP-B, 5´-cgtctagattacttgtacagctcgtccatg-3´ (with XbaI recognition site, underlined). This 
fragment after digestion (1,227 bp in length) was cloned into respective sites of pTRE-Tight 
(Clontech), giving rise to a vector pTe106 (GenBank accession number KX844812). For stable 
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cell transfections, the DNA of the pTe106 vector was used as a template for amplifying a linear 
transfection fragment 2,275 bp in length containing essential parts of the vector and omitting 
the unnecessary bacterial sequences, with primers TRE-Lin-FWD, 5´-
gaagcatttatcagggttattgtctc-3´ and TRE-Lin-REV, 5´-agggagaaaggcggacaggtatc-3´. 
4.3 Manipulations with Stem Cells   
The hESC line CCTL12 was cultured in monolayers on Matrigel as described 38. The 
karyotype of the cells was analyzed at Institut für Humangenetik und Anthropologie, Jena, 
Germany. For transfection of the stem cells, we initially employed the nucleofection (Lonza, 
Basel, Switzerland) and compared it to chemical transfection methods with FuGene 6, FuGene 
HD (Roche, Basel, Switzerland), Lipofectamine 2,000 (Thermo Fisher Scientific, Waltham, 
MA USA) and NanoJuice (Novagen/Merck Millipore, Darmstadt, Germany) reagents 
according to manufacturer protocols. For the pilot experiments, cells were transfected with 
pEGFP-N1 vector, and quantification of the efficiency of transfection was done by flow 
cytometry with Cytomics FC500 Flow Cytometry Analyzer (Beckman Coulter, Brea, CA, 
USA) 48 hrs post transfection by monitoring percentage of GFP positive cells. For this, cells 
were collected by TrypLE (Invitrogen/Thermo Fisher Scientific) and resuspended in 
conditioned HES medium 38 supplied with 10 µg/ml propidium iodide.  
For stable selection, a concentration of G-418 and Blasticidin selection agents were pre-
determined with killing curves, such that the sensitive (wild type) cells were slowly cleared 
away during two weeks. The killing curves were determined first in wide ranges and then in 
narrow ranges of concentrations. The G-418 was used at 140 µg/ml and Blasticidin at 1.2 µg/ml. 
The cells were plated at 20 000 cells/cm2 on Matrigel covered plates, and the selection agents 
were added 24 h post plating.  
The inducible overexpression in Tet-On system is regulated by rtTA transactivator, 
therefore in the first round of stable selection the cells were transfected with the HindIII 
linearized regulatory vector pEF1a-Tet3G (Clontech) and selected against G-418. For this, the 
cells were plated at 20,000 cells/cm2 into the 24x plate. 24 h post plating the cells were 
transfected with FuGene HD reagent. After additional 24h, the transfected cells were collected 
with Tryple and plated into 6x plate with 2-fold serial dilutions; and the selection agent was 
added 24h post plating. The medium was changed 2 times per week. Two weeks after, the 
individual colonies were collected and the dissociated cells were transferred to 96x well plates.  
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The growing colonies were divided into 3 parallel 96x plates, and the individual clones 
were screened for the efficiency of induction by transient transfection with pTRE-Luc vector 
(Clontech) followed by induction with DOX at 1 µg/ml and determination of luciferase signal 
using Bright-Glo Luciferase Assay System (Promega, Fitchburg, Wisconsin, United States). 
The luciferase signal was normalized to the metabolic activity of the cells in the same well 
determined by a resazurin assay. For this, the resazurin was added to each well at 5 µg/ml, and 
the fluorescence was determined with 595/535 nm excitation/emission wavelength, 
respectively after 4h incubation in a CO2 incubator at 37 ºC. The clones were screened for the 
lowest basal expression and the highest induction rate, as well as for their ability to retain their 
properties after cycles of cryopreservation. 
The cells of the selected stable clone E12-1 (positive for the rtTA transactivator) was 
further stably transfected with the pTe106 target vector. The transfection-selection procedure 
was similarly implemented as described above. As the pTe106 (a derivative of pTRE-Tight) 
vector does not possess any selection marker, its linear fragment (see above) was co-transfected 
with a Blasticidin linear selection marker. The linear selection marker for Blasticidin was 
obtained as a PCR fragment 1,309 bp long with primers BlastLin-A, 5´-
tataagggattttgccgatttcgg-3´ and BlastLin-B, 5´-gtatgttgtgtggaattgtgagc-3´ and DNA of vector 
pcDNA6/TR (Invitrogen) as a template. The resulting double-stable clone E12-1-1 
(overexpressing human FGF-2 in an inducible mode) was used in further experiments to support 
neuronal survival and regeneration. 
  
4.4 Human ESC Transplantation  
Immediately following neurorrhaphy, 3×105 hES cells resuspended in 3-5 µl of DMEM 
were engrafted directly at the lesion site together with the fibrin sealant matrix. To induce 
overexpression of FGF-2 in the hESCs in vitro, the inducer doxycycline was added to the growth 
medium at 1 µg/ml for 24-48 h. For experiments in vivo, DOX was given to animals combined 
with the pelleted food (see details above). Induction was confirmed by GFP expression in the 
hESCs.  
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4.5 Cell Culture  
The stems cells used in this research were hESCs derived in the Masaryk University 
(Dvorak, Dvorakova et al. 2006). The hESC line CCTL14 had been engineered such that the 
cells inducibly overexpress human fibroblast growth factor 2 (FGF-2 ) (Kyrylenko 2012).  
During the cell culture step, we first coated the plastic plates with Matrigel and produced 
proper surface for the cells to grow. Then, the frozen aliquot of Matrigel (Mgl) was diluted with 
DMEM on ice to reach 1/100 proportion. The whole surface of the well was covered by 
Mgl/DMEM solution and finally plated by Conditioned Human Embryonic stem cell (CHES, 
see below) medium. After applying the coating, we cultured the cells by following the 
successive steps outlined below:   
(i) the cryovial with HES cells was quickly thawed in a 37°c water bath;  
(ii) the content (cells) of the cryovial was transferred to the media for washing;  
(iii) the suspension was centrifuged and the cells were separated. 
(iv) the cells were re-suspended and then transferred to the prepared well; 
(v) the cells were cultivated in humidified incubator at 37°c with 5% CO2;  
(vi) after reaching the monolayer, the cells were detached by the TrypLE enzyme, collected, 
and washed.  
(vii) the cells were counted and 300,000 cells were prepared for follow-up surgeries. 
To prepare the CHES conditional medium, we derived mouse embryonic fibroblasts 
(MEFs) from 12.5 day embryos using the standard protocols available in our Lab. The MEFs 
were then frozen with the freezing medium and kept for subsequent medium preparations. Each 
time it was needed, we cultured them and then added HES medium to the MEF cells to make 
the CHES medium. The resultant CHES were used to culture the Human embryonic stem (HES) 
cells.  
4.6 Preparation and Administration of the Fibrin Sealant 
Fibrin sealant (FS) derived from snake venom was supplied by the Center for the Study 
of Venoms and Venomous Animals (CEVAP) of UNESP. Its constituents and instructions for 
use are provided in the patents No BR1020140114327 and BR1020140114360. At the time of 
usage, the components were thawed, reconstituted, and applied to the sciatic nerves (Barros, 
Ferreira et al. 2009, Barbizan, Castro et al. 2013),(Barbizan, Castro et al. 2013, Gasparotto, 
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Landim-Alvarenga et al. 2014). The fibrin glue, which is composed of three separate solutions, 
was homogenized immediately before being used in a final volume of 4.5 µl comprising of the 
following proportion: fibrinogen (2.5 µl), calcium chloride (1µl), and thrombin-like fraction (1 
µl). During the surgical procedure, the first two components were applied and the third 
component was added for polymerization. 
4.7 Immunohistochemistry 
In order to visualize the regenerating nerves, we employed immunohistochemistry 
technique. This approach enables the detailed observations of nerve regeneration mechanisms 
in mice. 
To accomplish this objective, the slides that were kept in a freezer at −20° C were 
removed and left at room temperature for a while and then were washed with 0.1M PB. Next, 
the specimens were incubated for 45 min in a 3% BSA solution. The resultant slides were 
incubated with the primary antibodies reported in Table 2 overnight at 4° C. After three washes 
in PB 0.1M, the respective secondary antibodies conjugated to Cy-3 (1/250, Jackson 
Immunoresearch, West Grove, PA, USA) were applied and incubated for 45 minutes at room 
temperature. Finally, the slides were washed and mounted with glycerol/PB (3:1) to obtain 
immunostained sections. 
 Table 2 – Primary antibodies used for immunohistochemistry. 
Antibody Supplier Host Code Concentration 
Anti-S100 Dako Rabbit Z0311 1/2000 
Anti-Neurofilament Milipore Rabbit Ab1989 1/2000 
Anti-VGLUT1 Synaptic system Rabbit 135303 1/1000 
Anti-ChAT Millipore Rabbit AB143 1/1200 
The immunostained sections were observed with a fluorescence microscope (Nikon 
Eclipse TS 100) using the rhodamine filter (CY3). Three representative images were captured 
from normal and regenerated nerves from different experimental groups using a high-sensitivity 
camera (Nikon DXM 1200F) mounted on the microscope. 
For quantification purpose, each immunelabeled picture was segmented into four sub-
images to avoid null margins and then measured to obtain the integrated density of pixels using 
IMAGEJ software (version 1.33u, National Institutes of Health, USA). For each animal, three 
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individual pictures from different parts of the nerve were collected. At the end, the mean 
intensity ± standard error was established by averaging the results of segments and pictures for 
each group. The results also were normalized against the control group (expressed in 
percentage) and used to compile the bar chart of the experimental groups. 
Immunohistochemistry analysis was performed aiming to quantify the following markers:  
(i) Anti-choline acetyltransferase (CHAT) to label motor fibers. 
(ii) Anti-neurofilament (NF) to observe regenerated axons; or analyzes the organization of 
the intermediary filaments that comprise the axons of regenerated and contralateral 
nerves. 
(iii) Anti-VGLUT1 to label primary afferent inputs. 
(iv) Anti S-100 to characterize the marker of Schwann cells. 
4.8 Catwalk Test 
Following the repair of peripheral nerve injury, improved behavioral outcome remains 
the most important evidence for the functionality of axon regeneration. The most frequently 
used behavioral test to evaluate sciatic nerve injury is the walking tract analysis from the 
Catwalk XT system (www.noldus.com/animal-behavior-research/products/catwalk). 
To perform this test, in a dark room, the animal is placed on a platform with a glass floor 
(with 100×15×0.6 cm dimension) fitted with a fluorescent lamp that is used to record points 
trodden by the mouse, and the amount of pressure exerted by his paw, which is directly 
proportional to the contact area of the foot to the floor. Through the glass, the floor of this 
corridor is monitored by a camera (Pulnix TM-765E CCD) equipped with a wide-angle lens. 
The signal intensity will vary according to the pressure applied by the animal's paw. The higher 
the pressure exerted by the animal's paw, the greater the paw contact with the floor and thus the 
higher the brightness, reflected in the intensity of pixels. These signals are digitized by PC 
Image-SG frame to frame (Matrix vision GmH, Oppenheime, Germany). The catwalk program 
acquires, stores and analyzes videos of animals roaming the hallway. 
The recorded videos were analyzed on a computer by CATWALK program. For the 
calculation of motor recovery rate of the sciatic nerve, the amounts related to the distances 
between the first and the fifth finger (toe spread), and between the third toe and the heel (print 
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length), both the right hind paws (normal) and left (injured) were applied to calculate the sciatic 
function index (SFI) by the following formula (Pan, Cheng et al. 2007):  
SFI = 118.9 ((ETS-NTS) / NTS) -51.2 ((EPL-NPL) / NPL) -7.5 
Where E is the injured side, N, the normal side, TS, the "toe spread," and PL, the "print 
length." For adaptation and training purposes, all animals are submitted to the test before the 
sciatic nerve injury. 
The Catwalk test and related calculations were performed for all the reported groups in 
Table 1 in the following way: at the beginning of one week interval until 14th day followed by 
four days intervals until reaching the limit of eight weeks (60 days).  
4.9 Von Frey Test 
Although Catwalk can serve as a standard tool for quantitative and reliable assessment 
of treatment efficacy (Chen, Cheng et al. 2014), it cannot measure pain, which is an indication 
of how good sensory neurons recover. To fill this gap, we considered to include electronic 
pressure-meter test (von Frey) to our experiments. This test was used to quantify the mechanical 
sensitivity of the feet following the surgery (Cunha, Verri Jr. et al. 2004, Shiotsuki, Yoshimi et 
al. 2010). 
To conduct this test, in a quiet room, mice are placed in individual Plexiglas’s box of 
12×20×17 cm in dimension, whose floor consists of a mesh network with a pore size of 5 mm2, 
and a non-malleable wire thickness of 1 mm. Mice remain in the boxes for 20 min before the 
experiment to habituate. Mirrors are positioned 25 cm below the testing boxes for easy viewing 
of the animal paws. 
The experimenter (the author) was trained to apply through the mesh network, pressure 
on the plantar surface of the paw at a constant increase until the mouse emit a paw withdrawal 
reflex, followed by a response characterized as tremor (“flinch”) of the stimulated paw. The 
stimuli were repeated until the animal shows three similar consecutive measurements (i.e. with 
a difference of force less than or equal to 10%). When the paw was withdrawn, the instrument 
automatically recorded the stimulus force. The maximal force applied was 8 g. The hyperalgesia 
intensity is evaluated by an electronic gauge, which consists of a force transducer connected to 
a digital counter and is quantified by variation of the nociceptive threshold in grams (gram-
force). 
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We measured the reflexes of the mice from groups # 1, 3, 4, 5, and 6 (Table 1) prior to 
the surgery to establish a baseline or preoperative sensory function. After performing the 
surgery, we repeatedly measured the same parameter for the duration of 8 weeks. However, 
during this time interval, due to a problem with the instrument, we failed to measure for two 
successive weeks. The three close measurements were averaged to represent the stimulus force 
(g) for each mouse. The results were analyzed by the statistical procedure described in section 
4-7. 
4.10 Statistical Analysis 
The results from all the noted experiments were presented as the mean ± standard error 
of the mean (SEM) and were evaluated by the analysis of variance method. We employed the 
one-way ANOVA by comparing track groups belonging to the same mouse strain over time by 
assuming a significance level equal to * P <0.05; ** P <0.01; *** P <0.001. In all cases, the 
ANOVA was followed by Bonferroni post-test. The resultant data were expressed as the mean 
± SEM with P<0.05 being considered to be significant. All statistical analyses were performed 
using the GraphPad Prism package (GraphPad Software, San Diego, CA, USA). 
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5. Results 
5.1 Expression of FGF-2 by hESCs  
We set a demonstration experiment in the lab to ensure that the addition of doxycycline 
activates the bioengineered cells to overexpress FGF-2. We cultured the cell in a plate and after 
reaching the monolayer, doxycycline was given to the medium at 1μg/ml concentration and 
after 24h examined them under a microscope using phase-contrast filter and florescence light 
(Fig. 4). The result clearly indicates that the cells have been activated and indeed can fulfill the 
expected functions. 
 
Fig. 4. Photographs of hESC activated by doxycycline to overexpress FGF-2. a) Using a phase-
contrast filter. b) By using florescence light. 
5.2 Immunohistochemistry 
Immunolabeling was performed on longitudinal sections of regenerated nerves after 60 
days post injury. By using anti-neurofilament antibody (Fig. 5), we analyzed the organization 
of the intermediate filaments that make up the axons of the regenerated, as well as the normal 
nerves. In all groups, the nerve fibers established a parallel pattern along the axis of the nerve, 
whereas in the intact (control) nerve, the fibers showed a pattern of parallel waves. Visually, 
the axons have their highest density in the ‘cell-on’ group (Fig. 5g) relative to other groups 
(~40% of the control group) and has the most similar pattern to control group (Fig. 5a and 5g). 
Nevertheless, statistical analysis performed for this antibody showed no significant difference 
between the experimental groups (Fig. 5h). The mean intensities of the immunostainings 
quantified by integrated pixel density are reported in Table 3. 
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Table 3  – The mean intensities of the immunostainings quantified by integrated pixel density 
for control and experimental groups.  
 
Antibody Anti-
VGLUT1 
Anti-S100 Anti-Neurofilament Anti-ChAT 
Control 192.6 ± 27.40 212.8 ± 21.3 726.3 ± 49.6 383.7 ± 82.0 
N 109.9 ± 11.30 392.7 ± 51.9 262.1 ± 14.6 222.7 ± 29.1 
N + F 101.4 ± 14.58 214.9 ± 27.5 199.4 ± 21.9 264.3 ± 27.4 
N + F + D 96.89 ± 9.256 159.9 ± 12.2 271.5 ± 37.5 260.7 ± 25.1 
N + F + W 131.8 ± 9.340 192.9 ± 9.7 239 ± 23.3 259.4 ± 31.8 
N + F + T 149.6 ± 6.576 260 ± 28.3 287.3 ± 35.5 275.6 ± 28.8 
N + F + D + 
T 
189.4 ± 20.13 204.6 ± 21.2 291.4 ± 33.3 289 ± 27.9 
  
Table 4 – The mean intensities of the immunostainings quantified by integrated pixel density 
for control and experimental groups. The normalized values were used to produce the graphs 
shown in Fig. 5-8. 
 
Antibody Anti-
VGLUT1 
Anti-S100 Anti-Neurofilament Anti-ChAT 
N (norm) 66.19 ± 7.752 150.6 
±15.67 
35.18 ± 2.189 47.66 ± 
5.526 
N + F (norm) 57.04 ± 9.484 100.5 ± 
9.04 
29.51 ± 3.091 50.26 ± 
7.681 
N+F+D(norm) 54.36 ± 6.536 80.04 ± 
6.90 
38.15 ± 2.819 48.95 ± 
5.090 
N+F+W(norm) 73.84 ± 6.312 96.24± 4.91 35.18 ± 3.739 53.51 ± 
7.145 
N+F+T(norm) 81.91 ± 10.41 131.5± 
16.37 
39.56 ± 1.682 56.79 ± 
6.056 
N+F+D+T(norm) 107.3 ± 15.88 99.7 ± 
12.42 
39.30 ± 4.336 61.13± 
5.792 
 
The Choline acetyltransferase (ChAT) as the enzyme responsible for the biosynthesis 
of acetylcholine is used currently as the most specific indicator for monitoring the functional 
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state of cholinergic neurons in the peripheral nervous systems. The Anti-ChAT is showing 
intense motor axons in the control group (Fig. 6a); albeit for the experimental groups, the motor 
axons are less intense. The mean intensities of the immunostainings quantified by integrated 
pixel density are reported in Table 3. Despite the incremental trend from ‘N+F’ (~43%) towards 
‘N+F+D+T’ group (~60%), statistical analysis performed for this antibody showed no 
significant differences between the groups. 
By means of Anti-VGLUT1 antibody (Fig. 7), which is a marker of sensory neurons, 
we labeled the primary afferent inputs responsible for transport of Glutamate into the synoptic 
vesicle. The observation with a fluorescence microscope indicated that VGLUT1 antibody is 
associated with a more sensory neuron in the ‘cell-on’ (N+F+D+T) group (Fig. 7G). The mean 
intensities of the immunostainings are reported in Table 3. Statistical analysis performed for 
this antibody showed statistically significant differences between the experimental groups with 
the ‘cell-on’ one having the highest integrated density. Based on this analysis, the ‘cell-on’ 
group is yielding the same level of sensory neurons as the control group, corresponding to 107% 
recovery (Fig. 7h).   
The anti-S100 µ-staining (Fig. 8) that is a characteristic marker of Schwann cells was 
intense on N and N+F+T groups (i.e. 150% and 120%, respectively), but in the group that 
incorporated transgenic cells was at the same level as the control group (i.e. 100%). The mean 
intensities of the immunolabels, quantified through the integrated density of pixels are reported 
in Table 3. Similar to VGLUT1 antibody, the statistical analysis shows a meaningful difference 
between the experimental groups.  
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Fig. 5. Anti-Neurofilament immuno-staining of the control nerves (A) and all groups (B to G), 
60 days after surgery. H) Quantification of the integrated density of pixels in the experimental 
groups relative to the control group presented in percentage (%) and calculated using IMAGEJ 
software. Statistically, there is no significant difference between the experimental groups. 
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Fig. 6. Anti-Chat immuno-staining of the control nerves (A) and all groups (B to G), 60 days 
after surgery. H) Quantification of the integrated density of pixels in the experimental groups 
relative to control group (%). Statistically, there is no significant difference between the 
experimental groups. 
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Fig. 7. Anti-VGLUT1 immuno-staining of the control nerves (A) and all groups (B to G), 60 
days after surgery. H) Quantification of the integrated density of pixels in the experimental 
groups relative to control group (%). Statistically, the difference between N+F vs N+F+D+T 
and N+F+D vs N+F+D+T groups are meaningful with P <0.05 and P <0.01, respectively. 
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Fig. 8. Anti-S100 immuno-staining of the control nerves (A) and all groups (B to G), 60 days 
after surgery. H) Quantification of the integrated density of pixels in the experimental groups 
relative to control group (%).Statistically, the difference between the following groups are 
meaningful: N vs N+F (p <0.05), N vs N+F+D (P<0.001), N vs N+F+W (P<0.05), and N vs 
N+F+D+T (P<0.05). The N vs N+F+T shows no significant difference. 
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5.3 Motor Evaluation of Functional Recovery via Catwalk 
The detailed results of Catwalk test separated by days and group are summarized in Fig. 9 
to 11. 
 
Fig. 9. The results achieved from Catwalk test separated by groups and calculated using the SFI 
index. a) Neurorrhaphy group. b) Neurorrhaphy + fibrin sealant. c) Neurorrhaphy + fibrin 
sealant + doxycycline. d) Neurorrhaphy + fibrin sealant + wild hESCs. e) Neurorrhaphy + fibrin 
sealant + transgenic cells. f) Neurorrhaphy + fibrin sealant + doxycycline + transgenic cells. 
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In all groups, in the first measurement session (7 days after the surgery), the SFI is in 
the lowest level of −75 (Fig. 9 and 10b), meaning that the mice cannot use their paws at all. 
However, after the second week, the changes just start. This is marked by a gradual increase in 
the SFI values in most of the groups (e.g. Fig. 9a and 9d). In the case of N+F group (Fig. 9b), 
the gradual increase in using the injured paw, which is indicated by a higher SFI value, drops 
after 4th session (day 22) and remains constant for the remaining duration of the experiment, 
whereas in the N+F+D group (Fig. 9c), this trend starts after 22 days and gradually increases 
afterwards. A similar trend can be seen in the N+F+W group (Fig. 9D). In contrast, the 
incremental trend in N+F+T and N+F+D+T groups (Fig. 9E and F) reverses after around 34-38 
days. 
In the pre-operation measurements (Fig. 10a and 11a), there are slight variations (5±2.5) 
in the SFI score of all groups that seemingly is due to the intrinsic error of the 
instrument/technique and also the personal walking habit of mice. Although the improvement 
of injured paws starts after around two weeks (14-18 days), the most noticeable changes begin 
after a month (between 34-38th days; Fig. 10H and 11B). However, the improvement is not 
sustainable and fluctuates between days. The improvement also is also highly variable among 
groups. The best scores belong to those groups that have incorporated hESCs (Fig. 11), whereas 
the group with no additive (N) compounds or a simple one like fibrin sealant (N+F) shows no 
recovery at all (Fig. 10 and 11).  
We calculated the P-value for Catwalk experiment separated by groups and days. When 
the one-way statistical test was performed for the results separated by days, except the 22th and 
34th days in which their P-values were significant (N vs N+F, N vs N+F+D, and N vs 
N+F+D+T with P<0.05 and N vs N+F+T with P<0.01 for day 22th and N+F vs N+F+T with 
P<0.05 for day 34th), the groups in other days showed no significant differences. Similarly, 
when the t-test was performed for the results separated by groups, only the N+F vs N+F+D 
(P<0.05), N+F vs N+F+W (P<0.01), and N+F vs N+F+T (P<0.01) showed significant 
differences. The general trend observed in Catwalk results, however, is the absence significant 
statistical difference among the experimental groups. 
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Fig. 10. The results achieved from Catwalk test separated by days and calculated using SFI 
index. a) preoperative results. b) day 7th. c) day 14th. d) day 18th. e) day 22th. f) day 26th. g) 
day 30th. h) day 34th. The abbreviations are as Table 1. In N+F+T group, the transgenic cell is 
‘off’ whereas in N+F+D+T group it is ‘on’. The box boundaries and whiskers indicate the mean 
± SEM and error bar, respectively. 
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Fig. 11. The results achieved from Catwalk test separated by days and calculated using SFI 
index. a) preoperative results. b) day 38th. c) day 42th. d) day 46th. e) day 50th. f) day 54th. g) 
day 58th. h) day 60th.Other explanations are as Fig. 10. 
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5.4 Sensory Function Evaluation via Von Frey Test 
The results obtained from von Frey test are shown in the Fig. 12. The pre-operative 
results for healthy mice commonly vary between 5-6 g (force), which is the case for all the 
groups shown in Fig. 12. Following sciatic nerve injury (first week) that leads to the loss of 
sense of the paw, the stimulus force reaches to a maximum of around 8 g. After this peak, the 
trend reverses and the required stimulus force decreases in several successive weeks until 
reaching a minimum in week 4. In groups in which transgenic cells were incorporated, the 
curves almost flatten after this minimum and show little change until the end of the period (Fig. 
12D and 12E).      
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Fig. 12. The results achieved from von Frey test during eight weeks of measurements separated 
by groups. The Preoperative represents the measurements before the surgery (treatment: 
P<0.05; time: p<0.001). 
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Fig. 13. The results of von Frey test for all groups during eight weeks period. 
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6. Discussion 
Peripheral nerve injury as a worldwide clinical problem could impair the quality of life 
of a patient. In contrast to CNS, the PNS is capable of repairing and regenerating after being 
injured. However, due to its structural complexity, the repair studies have been focused rather 
on animal models. Such pre-clinical examinations attempt to increase the tissue regeneration 
and functional recovery in the hope that eventually being translated to patients for improving 
clinical outcomes. The extensively used experimental model for this aim is based on injuring 
the sciatic nerve as the largest nerve trunk of mammals. This injury model provides a feasible 
system for studying nerve regeneration, remyelination, and functional recovery. However, the 
recovery from a severe nerve transection (i.e. autografting) is usually far more difficult and the 
results are less satisfactory (Cui, Jiang et al. 2008). To improve the recovery, transected nerves 
shall be surgically repaired to guide regenerating axons into the growth environment of the 
distal nerve stump. Even so, surgical repair often fails to achieve remarkable functional 
recovery in pre-clinical experiments. This is likely due to the decrease in the ability of neurons 
to sustain axon growth, and chronic Schwann cell atrophy with subsequent failure to provide a 
supportive growth environment (Bush, Tonge et al. 1996). To improve the degree of nerve 
regeneration and functional recovery, cell transplantation therapy has been used with some 
degree of success. In contrast to other varieties of stem cells, hESCs, have the ability to self-
renew indefinitely and differentiate into a diverse range of specialized cell types making them 
an important source for transplantation therapy and biomedical engineering (Weissman 2000, 
Cui, Jiang et al. 2008). 
Recent studies on the function and expression of FGF-2 and its receptors have revealed 
a physiological role for the molecules in the PNS. FGF-2 as a principal constituent of hESC 
growth medium is the most significant regulator of the hESC self-renewal. It is now widely 
accepted that the hESCs require exogenous FGF-2 to sustain self-renewal and pluripotency and 
develop the capacity to differentiate into a large number of somatic cell types. In practice, since 
it is difficult to deliver the active growth factors over the entire duration of regeneration in a 
controlled manner, genetically modified cells are used to deliver a continual supply of active 
growth factors. The gene expression in these modified cells was turned on by using doxycycline 
as the regulator for inducible gene expression systems. The effects of doxycycline were 
mediated by direct activation of the PI3K-AKT intracellular pathway. 
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Immunolabeling analysis is commonly used to identify the regenerated axons, Schwann cells, 
and proteins associated with nerve regeneration. The technique uses an antibody (e.g. Anti-
CHAT, Anti-neurofilament, Anti-VGLUT1, Anti-S100) for fluorescently labeling a specific 
biological target. When properly employed, the analysis can accurately determine the intensity 
and areal fraction of the regenerated nerve. 
The Immunolabeling results obtained after 60 days of cell therapy was indeed very 
promising. The study of nerves by anti-neurofilament antibodies demonstrated that the axons 
regenerated to some extent in all experimental groups. The highest nerve intensity and the most 
uniform pattern of axons were observed in the ‘cell-on’ group. The fact that all groups showed 
axon regeneration to some extent (around 40% of the control group) alongside with the absence 
of inter-group statistical differences imply that ‘autografting’ has been successful in stimulating 
fiber nerve regeneration. However, this antibody cannot indicate the type and accuracy of nerve 
sprouting. To distinguish between them, ChAT and VGLUT-1 antibodies were employed to 
label motor and sensory neurons, respectively. 
Based on anti-ChAT results, the minimum number of motor axons were observed in the 
N+F group meaning that fibrin sealant alone added to the site of injury offers no benefits to 
nerve regeneration. Whereas the ‘cell-on’ group does not stand out as a group with the best 
motor neuron regeneration, it possesses the highest recorded motor neurons (i.e. ~60% 
compared to control group). The fewer number of motor neurons after sciatic nerve transection 
is commonly reported in the literature (Wood, Kemp et al. 2011). In our research, statistical 
analysis revealed no statistical differences between experimental groups as well as between the 
‘cell-on’ and control group. This may suggest that cell therapy (hESC inducibly overexpressed 
FGF-2) alone is not quite sufficient to facilitate motoneuron recovery and there is a need for 
supplementary materials like neurotrophic factors to promote motoneuron regeneration. The 
adding of cells, however, has been very effective in sensory neuron reinnervation. For instance, 
the addition of wild and transgenic cells to the site of injury have increased the percentage of 
sensory neurons labeling respectively by 73 and 82% relative to control group (For comparison, 
this value for the neurorrhaphy-alone group was 66%). When the transgenic cells were activated 
by doxycycline, the intensity rate dramatically increased to the same level as a control group 
(~104%). This significant increase in nerve regeneration is believed to be linked to the 
expression of FGF-2 growth factor, because when doxycycline solely was added to the site of 
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injury (N+F+D group), it was not very effective in stimulating the regeneration. In the 
peripheral nervous system, FGF-2 modulates neuron survival, prevents the lesion-induced 
death of sensory neurons, and stimulates nerve regeneration (Jungnickel, Claus et al. 2004). 
The same group analyzed by S100 immunolabelling showed less activated Schwann cell and 
more axon regeneration. In fact, the density of Schwann cells was identical to control group 
(~100%) meaning that the combined effect of transgenic cells and fibrin sealant has been 
successful in integrating cells with the host tissue and expressing Schwann cell markers. This 
also suggests that the remyelination process was estimulated by the transplanted cells. 
Myelination, which determines both the regeneration quality and functional recovery, requires 
the secondarily developed Schwann cells by cell therapy to be wrapped longitudinal (Ren, 
Wang et al. 2012). 
As was marked by S100 antibody, except the neurorrhaphy group, all other groups that 
incorporated fibrin sealant glue showed normal intensity of Schwann cells and thus a more 
stable endoneural microenvironment. Whereas Pabari et. al. (Pabari, Lloyd-Hughes et al. 2014) 
have demonstrated the constructive role of fibrin sealants in producing less inflammation, less 
fibrosis, better axonal regeneration, and better fiber alignment, based on our 
immunohistochemistry results, we can only confirm its crucial role in reducing inflammationan 
and establishing a framework capable of retaining the grafted cells. This is corroborated by the 
absence of statistical differences between the neurorrhaphy-alone group and others in the 
outcomes of neurofilament immunolabeling.  
In the context of behavioral patterns, in the first week after the surgery, as expected, 
none of the mice were able to use their paws and thus the SFI values obtained from Catwalk 
test were equal to -75. This is due to total loss of function of the nerve after neurorrhaphy and 
indeed a clue for successful lesion/repair process (Félix, Pereira Lopes et al. 2013). In most of 
the groups, it took about a month (26-30 days) for the mice to be able to use their paws. For 
some groups that were able to use their paws, however, due to likely inflammation and relevant 
pain, they stopped to use their paws altogether, so the recovery expressed by SFI was again 
back to −75. The inflammation/hyperalgesia hypothesis is further supported by the results from 
von-Frey test (Cunha, Verri Jr. et al. 2004). Coincidently, at fourth week, the force to stimulate 
the nerve reflex reduces to their minimum of about 4gf. It is important to highlight that, in fully 
denervated muscle, the highest level of post-synaptic sprouts occurs at four weeks after injury 
and repair (Wood, Kemp et al. 2011). This could further explain the hypersensitivity of mice to 
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pain at this specific time. In the anti-S100 immunolabeling performed after eight weeks, 
however, no such inflammation was recorded, specifically in the ‘cell-on’ group, meaning that 
the likely inflammation was reduced during the time. After a sudden drop in week 4, the sensory 
function of the paws were recovering, hence the force needed to stimulate the nerve reflex was 
gradually coming back to normal (~ 6gf). This timing conform to the finding of anti-S100 
immunolabeling. 
Despite the slight initial improvement, group #2 (N+F) showed no recovery in the nerve 
function. The SFI score from this group remained close to -75 after 26 days in almost all 
subjects, which is evident by a flattened trend in the diagram. The fact that the results of this 
group show no advantages relative to the neurorrhaphy-alone group (#1; N) implies that the 
inclusion of mere fibrin sealant in the site of injury has no recovery effects. This finding indeed 
is in agreement with the results of immunohistochemistry discussed above. The results from 
group #1, however, are not straightforward. Despite some slight improvement in functional 
recovery in the middle of the period, the SFI from this group at the final days turns back to −75. 
In general, though, these two groups revealed no functional recovery.   
Among the studied groups, those that included doxycycline, wild hESC, and transgenic 
cells achieved better results. All these groups showed recovery to some extent from the first 
month onward, though the results were not stable and were varied between measurement 
sessions. Parts of the fluctuation in the SFI level could be assigned to uncertainties in instrument 
function and quantification (classification) technique. The other part is linked to mice status 
and habit. For instance, a stressed mouse may walk abnormally on the walkway which may lead 
to variations in the results between sessions. Furthermore, those parts of the classification that 
rely on experimenter (e.g. footprint detection) can be subject to variations during the time. Such 
inherent variations can be easily seen in the graph of healthy mice before undergoing surgery. 
Moreover, the fluctuation in the number of regenerating nerves and surviving motoneurons over 
time (Ma, Omura et al. 2011) could alter the behavioral patterns of the settings.  
The reversal of SFI in the N+F+T and N+F+D+T groups, however, is linked to more 
painful paws arising from higher sensory nerve regeneration as was demonstrated by 
immunohistochemistry studies and von-Frey test. The neuropathic pain is known to develop 
after sciatic nerve injury, hence differences in SFI levels may not only reflect motor-related 
impairments, but also be pain-related due to decreased weight load on the affected paw 
(Medhurst, Walker et al. 2002, Deumens, Jaken et al. 2007). As was stated by Deumens. et al. 
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(Deumens, Jaken et al. 2007), “functional impairments may be purely related to pain behavior 
and the behavioral effects may be a compromise between pain-related and motor-related 
alterations”. Following autografting, the mice started to use their heel to contact the ground 
rather than their toes. The origin of this behavior is believed to be motor-related, rather than 
pain related for it began within days after injury, whereas pain sensitivity, as indicated by von-
Frey test, was only observed after a delay of about 3-4 weeks. Recovery of pain sensitivity was 
also corroborated by toe pinch reflex test on awake mice. The animals displayed a blink reflex 
or a withdrawal response to light paw-pinching. 
Despite significant advances in the understanding of the nerve regeneration and repair 
in surgical techniques, complete functional recovery of a damaged nerve seems to be scarce. 
The poor functional recovery is likely due to: (i) the failure of regenerating axons to cross the 
gap between proximal and distal nerve coaptation and (ii) the cross-innervation 
(mismatch/dislocation) of the regenerated axons within the peripheral target sites (e.g. muscle 
and tendon) (Scott 1996). In the current study, the results obtained from von-Frey sensory test 
and immunohistochemistry (anti-neurofilament) denoted that axon regeneration has occurred 
across the autographed gap, particularly in the ‘cell-on’ group; however, it was not as dense as 
the control group. This signifies that certain numbers of axons have failed to reach end organs 
and thereby the fewer regenerated axons have expressed their terminal branching capacity 
(Meek, Den Dunnen et al. 1999). The consequence of this phenomenon would be the alteration 
of the motor unit organization by clumping of the muscle fibers (Meek, Den Dunnen et al. 
1999). Clumping may lead to changes in the force distribution profile of the muscle during 
contraction and influence the mechanical input to the tendon organs (Scott, Davies et al. 1995) 
and thus the feedback of walking track patterns. The other reason for muscle imbalance and a 
low recovery could be the misdirection of degenerating nerve fibers in the target regions (Meek, 
Den Dunnen et al. 1999) as autografting transects closely intertwined sensory and motor 
neurons. A major key to functional recovery is the accurate regeneration of axons to their 
original target end-organs. 
Overall, the low levels of SFI in our experiment could be attributed to the following 
factors: (i) the feel of pain in the injured organ; (ii) the sensitivity of the system in recording 
the full footprint of paw only; (iii) the natural fluctuation in the number of regenerated motor 
neurons over time, and (iv) imperfect nerve regeneration and mismatching between sensory and 
motor neurons. The sensory component is very significant for correct motor coordination and 
control and thus higher functional recovery (Benitez, Barbizan et al. 2014), albeit the 
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simultaneous pain arising from sensory neuron recovery can hinder the proper use of paw and 
thereby leads to lower SFI score. This issue could be resolved by using painkiller during the 
experiment. The second obstacle could be avoided by using the analogue walking track 
technique instead of the Catwalk XT system. We speculate the hESCs have the capability to 
improve and stabilize nerve regeneration. However, to witness this, the effects of the first two 
factors should be eliminated primarily. 
Catwalk test has been successfully used for sciatic nerve crush and spinal cord injury 
models (Bozkurt, Deumens et al. 2008, Benitez, Barbizan et al. 2014). As an example, the 
functional recovery of dorsal root avulsion, which is a more severe injury than autografting, has 
been successfully shown via Catwalk test. However, in the case of complete sciatic nerve injury 
via autografting that is the subject of this research, Catwalk was not successful in showing the 
functional recovery despite clear signs of nerve regeneration given by complementary 
techniques. We speculate that the animal cannot use the complete plantar surface of its paw for 
walking and instead it uses the heel in the early days after surgery and thereafter the front part 
of the paw including toes. The Catwalk XT system is programmed to differentiate the way the 
animal uses its paw and thus the front part of the paw of the injured animal that barely carries 
body weight may be considered below the detection threshold and not recorded. Whereas the 
SFI yielded from the walking track analysis is not sensitive to the part of the paw carrying the 
body weight (Deumens, Jaken et al. 2007). We believe this fundamental difference makes the 
analogue technique more viable for nerve regeneration evaluation following end-to-end 
neurorrhaphy. 
To our knowledge, this is the first time that sciatic nerve regeneration has been evaluated 
by combined behavioral tests namely von-Frey and Catwalk in a mouse model. The former can 
provide information on sensory nerve regeneration whereas the latter (or its substitute; the 
walking track analysis) gives information about motor neuron regeneration and their 
aggregation translated into functional recovery. 
Regarding the duration of nerve regeneration, in a rat model, some studies have been 
carried on for more than 52 weeks (Meek, Den Dunnen et al. 1999). In rodent models of nerve 
regeneration, “chronically denervated distal stumps already have an impaired capacity to 
support axonal outgrowth by eight weeks after the injury” (Scheib and Hoke 2013). However, 
in mice model, there is a critical window of approximately 35 days, in which regenerating axons 
can re-establish connections with the distal muscles. Since the tissues are most permissive to 
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reinnervation during this period, any increase in the rate of axon extension could facilitate axons 
to reach their targets (Ma, Omura et al. 2011). At around the same time, a local peak in the SFI 
scores is noticeable in our results. On the other hand, by assuming an axon regeneration rate of 
up to 3 mm/day (Brushart, Hoffman et al. 2002), and autografting as the optimal suture 
technique, regenerating axons could be expected to reach the distal part of the nerve graft after 
3-6 weeks of the surgery, albeit, reinnervation of muscles and improved functional recovery 
would require longer times of about 12 weeks (Bozkurt, Tholl et al. 2008). Accordingly, higher 
levels of SFI could be expected for our experimental groups if the studies were continued for 
longer than eight weeks. 
Functional recovery after complete nerve injury depends on several factors including 
regrowth of axons, specific reinnervation of the target region, and maturation of nerve fibers 
and reinnervated muscle fibers (Krarup, Archibald et al. 2002, Krarup, Boeckstyns et al. 2016). 
Reinnervation of muscle fibers includes the establishment of neuromuscular connections and 
formation of motor units as an essential element of force development and movement control. 
In this phase, nerve fibers should grow from the proximal nerve stump and reconnect to muscle 
fibers. Naturally, nerve fibers incorporate a small number of muscle fibers, however, during the 
nerve regeneration, the muscle fibers group within the same motor unit and correspondingly, 
regenerated axons incorporate additional muscle fibers. These fibers that bear the same 
biochemical signatures compensate for reduced numbers of axons that succeed in reaching the 
denervated muscle (Wood, Kemp et al. 2011). The fact that motor axons reinnervate (enlarge) 
more than the normal number of muscle fibers causes all denervated muscle fibers to be 
innervated by as few as 20-25% of the normal number of motor axons (Wood, Kemp et al. 
2011). Nevertheless, reduced numbers of regenerating nerves give rise to a failure to reinnervate 
all the denervated muscle fibers, thus declining the muscle contractile force. As a consequence, 
poor functional recovery is recorded by catwalk experiment. In other words, the absence of 
functional recovery does not necessarily mean a failure in nerve regeneration. Instead, “the 
misdirection of regenerating axons (inaccurate reinnervation) could strongly affect sensory-
motor skills, which require accurate reinnervation of the proper muscles and receptors, whereas 
gross functional responses are more dependent on the amount of reinnervation rather than its 
accuracy” (Navarro 2016). The poor functional recovery problem is also compounded by 
inaccurate (misdirection) regeneration of axons (Wood, Kemp et al. 2011). Under conditions 
where the numbers of regenerated axons and reinnervated muscle fibers decline below the noted 
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level, reinnervated muscles fail to recover contractile force and thus functional recovery 
remains at low levels (Wood, Kemp et al. 2011).  
In the clinical situation, patients normally “reprogram” their brain to cope with an 
altered input of information. Meek et. al. (Lundborg 1993, Meek, Den Dunnen et al. 1999) 
argued that the reprograming of the brain can explain improvements in the SFI values of rat 
model in long-term (i.e. 52 weeks) examinations. The brain reprograming is also linked to the 
recovery of coordination in hind paw of rats (Bozkurt, Scheffel et al. 2011). In our mouse 
model, the FGF-2 facilitates the growth of sensory neurons and thus the mice feel pain (as 
indicated by von-Frey test and anti-VGLUT-1 immunolabeling). We believe if the pain is 
relieved by painkiller, then due to combined effect of nerve regeneration and reprograming, one 
can expect higher values for SFI after longer recovery periods. 
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7. Conclusion 
 
A new therapeutic approach for sciatic nerve regeneration in mice model was adopted 
in the present work. The approach includes the application of human embryonic stem cells 
(hESCs) modified to inducibly overexpress FGF-2 to the site of injury resulted from end-to-
end neurorrhaphy. The transgenic hESCs activated by doxycycline were successful in the 
regeneration of sensory function and promotion of axonal reinnervation as demonstrated by 
von-Frey test and immunohistochemistry analysis. The Catwalk system, however, was not 
successful in showing the functional recovery despite clear indications of nerve regeneration 
provided by complementary techniques. We believe this failure results from two key factors: 
(i) the incapability of Catwalk XT system to record partial usage of the paw and incomplete 
footprints; and (ii) pain (hyperalgesia) in the mice’s paw arising from the regeneration of 
sensory fibers. To resolve the former issues, future studies shall evaluate the behavioral function 
using the analogue walking track analysis. To relieve the pain of the animals, a painkiller such 
as Tramadol should be used during the analysis. Our work indicated that the simultaneous use 
of sensory test (von-Frey) and walking track analysis provide a more detailed picture of sciatic 
nerve recovery, and thus it shall be incorporated in future works. 
Based on this study, fibrin sealant is capable of reducing inflammation and likely can 
facilitate nerve fiber alignment. However, we found no evidence of its participation in axonal 
regeneration in the particular experimental setup. While the mixture of this glue and transgenic 
cells yielded to very promising results in regeneration of sensory function, we believe that for 
higher functional recovery and better motor neuron reinnervation, these agents should be used 
in combination with neurotrophic factors such as NGF, CNTF, GDNF, and BDNF (Chen, Chu 
et al. 2010). Axon counting, albeit not performed in this work, should accompany the noted 
settings to help evaluate the rate of regenerative success. It is worth mentioning that 
reinnervation of muscles and improved functional recovery would require longer times of about 
12 weeks (Bozkurt, Tholl et al. 2008). Accordingly, higher functional recovery could be 
expected for similar experiments in case the studies continued for a longer time. 
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